GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » 12-1 Month Momentum %

I-MAB (IMAB) 12-1 Month Momentum % : -39.06% (As of May. 14, 2024)


View and export this data going back to 2020. Start your Free Trial

What is I-MAB 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-14), I-MAB's 12-1 Month Momentum % is -39.06%.

The industry rank for I-MAB's 12-1 Month Momentum % or its related term are showing as below:

IMAB's 12-1 Month Momentum % is ranked worse than
65.46% of 1488 companies
in the Biotechnology industry
Industry Median: -22.915 vs IMAB: -39.06

Competitive Comparison of I-MAB's 12-1 Month Momentum %

For the Biotechnology subindustry, I-MAB's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


I-MAB's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where I-MAB's 12-1 Month Momentum % falls into.



I-MAB  (NAS:IMAB) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


I-MAB  (NAS:IMAB) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


I-MAB 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of I-MAB's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


I-MAB (IMAB) Business Description

Industry
Traded in Other Exchanges
Address
555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.